EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression



RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression



American Journal of Pathology 178(6): 2845-2856



Recent findings have focused attention on the molecular consequences of the microenvironment in tumor progression, but events occurring in cancer cells themselves in response to their ambient conditions remain obscure. Here, we identify receptor activator of nuclear factor κB ligand (RANKL) as a microenvironment-specific factor essential for tumorigenesis in vivo, using head and neck squamous cell carcinoma (HNSCC) as a model. In human HNSCC tissues, RANKL is abundantly expressed, and its expression level correlates with the histological grade of differentiation. RANKL levels are significantly higher in poorly differentiated SCCs than in well or moderately differentiated SCCs. In contrast, all HNSCC cell lines tested displayed extremely low RANKL expression; however, RANKL is efficiently up-regulated when these cell lines are inoculated in the head and neck region of mice. RANKL expression is restored in a microenvironment-specific manner, and cannot be observed when the cells are inoculated in the hindlimbs. Forced expression of RANKL compensates for tumor growth in the hindlimb milieu, promotes epithelial mesenchymal transition, and induces tumor angiogenesis, in a manner independent of vascular endothelial growth factor (VEGF). These results implicate RANKL expression causatively in tumor growth and progression in HNSCC in vivo. RANKL may provide a novel functional marker for biological malignancy and a therapeutic target based on the specific nature of the microenvironment.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333164

Download citation: RISBibTeXText

PMID: 21561598

DOI: 10.1016/j.ajpath.2011.02.003



Related references

USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer 88(3): 239-245, 2016

Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Science 99(5): 905-913, 2008

Wnt3a expression is associated with epithelial-mesenchymal transition and promotes colon cancer progression. Journal of Experimental & Clinical Cancer Research 33(): 107-107, 2015

BI 5700, a Selective Chemical Inhibitor of IκB Kinase 2, Specifically Suppresses Epithelial-Mesenchymal Transition and Metastasis in Mouse Models of Tumor Progression. Genes & Cancer 1(2): 101-114, 2010

Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Molecular and Cellular Biology 21(2): 575-594, 2001

Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma. Medical Oncology 31(9): 181-181, 2015

Loss of abhd5 promotes colorectal tumor development and progression by inducing aerobic glycolysis and epithelial-mesenchymal transition. Cell Reports 9(5): 1798-1811, 2015

RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition. Plos One 9(9): E108507-E108507, 2015

A biomaterial model of tumor stromal microenvironment promotes mesenchymal morphology but not epithelial to mesenchymal transition in epithelial cells. Acta Biomaterialia 10(11): 4811-4821, 2015

Expression of receptors tyrosine kinase c-kit and EGF-R in colorectal adenocarcinomas: is there a relationship with epithelial-mesenchymal transition during tumor progression?. Langenbeck's Archives of Surgery 394(6): 1131-2; Author Reply 1133-4, 2010

Over-expression of regulator of G protein signaling 5 promotes tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma cells. Journal of Surgical Oncology 108(3): 192-196, 2013

FYN promotes breast cancer progression through epithelial-mesenchymal transition. Oncology Reports 36(2): 1000-1006, 2016

NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. Oncotarget (): -, 2016

MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. Molecular Cancer 13(): 245-245, 2015

OTX1 promotes colorectal cancer progression through epithelial-mesenchymal transition. Biochemical and Biophysical Research Communications 444(1): 1-5, 2014